Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25616986 | 0.80 | NPC1 (0.34) | RAB9ANPC1PKMLMNAALDH1A1 | |
| SCHEMBL25075159 | 0.78 | ALDH1A1 (0.40) | RAB9AGAANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL31312336 | 0.75 | LIPG (0.38) | RAB9ANPC1MAPTLMNAALDH1A1 | |
| SCHEMBL24968316 | 0.71 | CYP11B1 (0.31) | — | |
| SCHEMBL21522060 | 0.71 | NPC1 (0.39) | RAB9ANPC1KMT2AMAPTPKM | |
| SCHEMBL21519273 | 0.70 | NPC1 (0.50) | RAB9AGAANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL21521058 | 0.70 | HTT (0.49) | RAB9AGAANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL26439242 | 0.70 | — | — | |
| SCHEMBL30725991 | 0.69 | ELOVL1 (0.40) | ELOVL1 | |
| SCHEMBL21521103 | 0.69 | NPC1 (0.37) | RAB9ANPC1KMT2AMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | RAB9A 4468/4885GAA 3492/4885NPC1 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.